CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1 Terminated 23 enrolled Cullinan Therapeutics Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors

Timeline

Start: 2023-12-12
Primary completion: 2026-06-16
Completion: 2026-06-16

Outcome

Outcome not reported

Stopped: “Company decision”

Publications

Mehta NK, Rakhra K, Meetze KA, Li B, Momin N, Chang JYH, Wittrup KD, Baeuerle PA, Michaelson JS. CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity. Cancer Immunol Res. 2024 Aug 1;12(8):1022-1038. doi: 10.1158/2326-6066.CIR-23-0636.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CLN-617	Protein / enzyme biologic	—	Other
Subject	Pembrolizumab	Monoclonal antibody	—	—